(Q44546527)

4 December 2017

title

[Acarbose for prevention of diabetes mellitus. STOP-NIDDM]]. (English)

1 reference

4 December 2017

E Windler

1

1 reference

4 December 2017

language of work or name

German

0 references

publication date

1 April 2003

1 reference

4 December 2017

1 reference

4 December 2017

volume

44

1 reference

4 December 2017

issue

4

1 reference

4 December 2017

page(s)

491-493

1 reference

American Diabetes Association diabetes diagnostic criteria, advancing age, and cardiovascular disease risk profiles: results from the Third National Health and Nutrition Examination Survey.

4 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00108-003-0871-2

Diabetes Intervention Study. Multi-intervention trial in newly diagnosed NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00108-003-0871-2

The 1997 American Diabetes Association criteria versus the 1985 World Health Organization criteria for the diagnosis of abnormal glucose tolerance: poor agreement in the Hoorn Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00108-003-0871-2

Risk of diabetes in the new diagnostic category of impaired fasting glucose: a prospective analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00108-003-0871-2

Safety and efficacy of acarbose in the treatment of Type 2 diabetes: data from a 5-year surveillance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00108-003-0871-2

The effect of acarbose on insulin sensitivity and proinsulin in overweight subjects with impaired glucose tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00108-003-0871-2

Effect of acarbose on insulin sensitivity in elderly patients with diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00108-003-0871-2

The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insuli

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00108-003-0871-2

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00108-003-0871-2

Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00108-003-0871-2

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00108-003-0871-2

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00108-003-0871-2

Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention

21 January 2018

1 reference

12 December 2020

The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance

1 reference

12 December 2020

Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe

1 reference

12 December 2020

Glucosidase inhibition. A new approach to the treatment of diabetes, obesity, and hyperlipoproteinaemia

1 reference

12 December 2020

10.1007/S00108-003-0871-2

Identifiers

DOI

1 reference

4 December 2017

1 reference